Market research
CRVO CervoMed Inc.
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 39M
- P/E ratio
- Not available
- Analyst target
- 15.4
- Dividend yield
- Not available
- Beta
- -4.31
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US15713L1098
- Market cap
- 39M
- P/E ratio
- Not available
- Analyst target
- 15.4
- Dividend yield
- Not available
- Beta
- -4.31
About
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the CRVO discussion.
No comments yet
Start a focused discussion about CRVO.